What Фосфадена Таблетки Treats: Main Uses and Benefits

Фосфадена таблетки (Adenosine Phosphate) is applied across domains where additional symptomatic support is needed, primarily in contexts marked by increased discomfort or functional tension. Its use is relevant in situations that involve chronic circulatory deficits and metabolic stress. Within anti-ischemic contexts, its application is associated with conditions like chronic coronary insufficiency, the post-infarction state (cardiosclerosis), and chronic peripheral artery disease.

This medication is commonly used to help with symptom clusters that create noticeable physiological strain, such as effort-related ischemic discomfort and the severe pain and cramping in leg muscles known as intermittent claudication. It also may be part of symptomatic management for specific degenerative ophthalmological conditions, including macular degeneration. Providing supportive relief when symptoms interfere with routine activities, it assists with maintaining functional stability and supports patients during episodes of heightened discomfort.

---

Quick Fact: Symptomatic Support for Chronic Conditions
Symptom Domain: Symptoms related to organ-specific functional stress (heart, limbs, retina)
Common Clinical Contexts: Conditions characterized by periods of heightened symptoms, such as effort angina
Patient-Oriented Benefit: Assists with maintaining functional stability and contributes to easing the overall symptom load

---

Regulatory References

1. NIH StatPearls overview on Adenosine

Eligibility Profile: Who Can and Cannot Use Фосфадена Таблетки

The eligibility for Фосфадена таблетки (Adenosine Phosphate) is defined by strict regulatory criteria, classifying populations as permitted, restricted, or absolutely contraindicated. Use of this medication is generally permitted for adult patients (18 years and older) with approved chronic conditions.

Absolute Contraindications

Official labeling prohibits use in patients with certain severe pre-existing conditions. These contraindications include:

• Known hypersensitivity to the active substance or excipients.
• Severe cardiovascular issues, such as Second- or Third-Degree Atrioventricular (AV) Block or Sick Sinus Syndrome (without a functional pacemaker), and Severe Arterial Hypotension.
• Specific metabolic disorders, including Hyperuricemia or active Gout.
• Acute clinical states like recent Acute Myocardial Infarction or Hemorrhagic Stroke.

Age and Physiological Restrictions

Use is contraindicated in the pediatric population (children and adolescents under 18 years) because safety and efficacy have not been established. The medicine is not recommended for women who are pregnant or breastfeeding due to insufficient human safety data. Use in patients with pre-existing conditions like First-Degree AV Block or Hepatic/Renal Impairment requires specific caution and monitoring.

Interactions with other medicines and products

This section summarizes documented interactions for Фосфадена (Adenosine Monophosphate) based on authoritative regulatory information, focusing on substances that modulate the activity or clearance of the active moiety, Adenosine.

Clinically Significant Interacting Agents

Interaction Type	Interacting Substance/Class	Effect Description	Management Requirement
Potentiation	Dipyridamole (Nucleoside Transport Inhibitor)	Significantly increases Adenosine exposure and effect.	Withholding Dipyridamole for at least 24 hours is required.
Antagonism	Methylxanthines ( Theophylline, Caffeine)	Blocks Adenosine receptors, reducing drug effectiveness.	Withholding Methylxanthines for five half-lives is typically required.
Additive Effects	Carbamazepine, Cardiac Conduction Agents	May combine with Adenosine to cause excessive depressant effects on cardiac conduction.	Use with caution; patient monitoring may be required.

Additional Considerations

The most critical interactions involve agents that disrupt Adenosine metabolism or receptor binding. Dipyridamole restricts the rapid cellular uptake and elimination of Adenosine, leading to intensified effects. Conversely, Caffeine and other methylxanthines, found in certain foods and medications, act as antagonists, directly blocking the drug's intended action. Due to these interactions, specific time separation rules are mandated for co-administration of these substance classes to avoid severe potentiation or antagonism.

Фосфадена (Phosphaden) is adenosine monophosphate (AMP), an endogenous nucleoside monophosphate. Upon systemic introduction, the molecule is metabolized and incorporated into fundamental cellular bioenergetic and signaling processes, primarily acting as a metabolic substrate.

Its action centers on providing a precursor for the synthesis of adenosine triphosphate (ATP), which is the primary molecular currency of intracellular energy transfer, regulating numerous endothermic reactions essential for cellular function. AMP is also a constituent of key coenzymes that regulate intracellular oxidation-reduction (redox) processes within tissues. Furthermore, AMP directly and indirectly modulates the synthesis of porphyrins, including its regulatory role in the formation of aminolevulinic acid and its subsequent conversion into protoporphyrin.

At the system level, adenosine derivatives act as agonists at P1 (adenosine) receptors, specifically A2A receptors on vascular smooth muscle, triggering adenylyl cyclase activation and increasing intracellular cAMP concentration. This downstream cascade leads to vasodilation and a subsequent improvement in both macro- and microcirculation. It also exhibits antiplatelet effects, modifying platelet aggregation, which, in conjunction with enhanced tissue metabolism and perfusion, facilitates tissue trophic support and regeneration processes.

How to use Фосфадена таблетки

The administration of Фосфадена таблетки (Adenosine Phosphate) is based on a structured course of therapy. The medicine is available as tablets for oral administration, although the therapeutic protocol for the active ingredient often incorporates an injectable solution for initial treatment, reflecting a dual-route administration scope.

The regimen frequently employs a sequential treatment structure. This means a course of therapy may begin with a short period of non-oral administration, followed by a transition to the oral tablets to complete the treatment. The single oral dose is typically 25 mg to 50 mg per tablet.

When used for maintenance, the schedule supports a divided daily dose, often requiring the oral tablets (e.g., 50 mg strength) to be taken up to 4 times per day to achieve the required daily input. The overall duration for a single treatment cycle is standardized and typically lasts between two and four weeks.

Prescribing documentation focuses on administration logistics. Available data does not explicitly detail specific, mandatory dose adjustments for populations such as older adults or those with renal or hepatic impairment. Regarding practical intake, the tablets are intended to be swallowed whole, and instructions do not specify a requirement for intake with or without food.

Research Evidence / Overview of Studies for Фосфадена таблетки

---

Evidence for use in Angina Pectoris (Стенокардия)

Research was studied for its use in patients with conditions characterized by fluctuating or episodic manifestations, such as angina pectoris (chest pain). These trials frequently involved controlled study designs where the agent was evaluated in patients experiencing outcomes related to physical discomfort and outcomes describing episodic or acute changes. Studies describe patterns in measurements taken over defined time intervals, reflecting the frequency of episodes and the physiological strain that occurred.

While studies are part of the broader evidence landscape, the follow-up durations were limited. Therefore, the long-term effects are not fully established regarding the sustained course of this condition. The existing research provides context but not individual predictions.

---

Evidence for use in Vascular Diseases of the Limbs (Сосудистые заболевания конечностей)

Research was evaluated in patients with conditions marked by functional limitations, such as chronic diseases of the arteries and veins in the limbs. The research examined outcomes reflecting daily functioning or activity level and measures linked to systemic imbalance. The data describe measurements related to how daily functioning was assessed during the short time intervals of the research.

Heterogeneity in study design and conduct was observed across the available research, and the sample sizes were modest in some literature. The results apply only to the populations studied and do not provide sufficient information for all subgroups of these vascular conditions.

---

Evidence for use in Hepatic and Metabolic Conditions (Заболевания печени и обмена веществ)

The agent was studied for its use as part of complex therapeutic approaches for certain liver diseases (like chronic hepatitis) and metabolic disorders. Researchers monitored specific biomarkers and outcomes related to systemic or functional imbalance. This evidence describes symptom patterns in patients with these complex, chronic conditions. Evidence is limited for this application, particularly in large-scale studies. The long-term effects are not fully established when using the agent for these chronic systemic conditions.

---

What is still uncertain about Фосфадена таблетки

The data are still emerging in certain areas of use, and certainty remains low regarding some of the less-studied indications. A key gap is that comparative evidence is lacking in some areas against contemporary standard treatments. Furthermore, the sample sizes were modest across various studies, meaning the data may not apply widely.

Key Studies & References

1. Official Drug Monograph and Instructions for Medical Use: Phosfaden (Фосфадена)

Common questions about Фосфадена таблетки (FAQ)

---

Q: What should I do if I forget to take my daily dose of Фосфадена?

Official prescribing information typically includes instructions for how to handle a missed dose. For oral tablets, the label generally specifies a time frame to decide whether to take the missed dose or wait for the next scheduled dose. If a dose is missed, patients are generally advised to consult the Patient Information Leaflet or their medication's official instructions for the specific guidance provided for this product.

---

Q: Can I crush or chew Фосфадена tablets, or do they need to be swallowed whole?

The official product information states that Фосфадена tablets are intended to be swallowed whole. Unless explicitly stated otherwise in the drug label, regulatory standards indicate that crushing, splitting, or chewing the tablets should be avoided, as this may impact how the medicine is absorbed.

---

Q: If I experience flushing while taking Фосфадена tablets, what should I do to manage or stop it?

Regulatory documents list flushing (facial redness) as a common, expected reaction to this medicine. This effect is often described as transient or self-limiting, meaning it is temporary and resolves on its own. Official labeling generally notes the transient nature of this effect and typically advises seeking medical attention if the effect becomes severe, persistent, or concerning.

---

Q: How should I store Фосфадена tablets if I am traveling to a hot climate?

The official storage requirements specify that Фосфадена tablets must not be stored above 25, C (77, F). When traveling, it is necessary to ensure the medication is kept protected from heat, light, and moisture to maintain its quality and effectiveness, as adherence to the required temperature range is a critical regulatory standard.

---

Q: Is it safe to drive or operate machinery while taking Фосфадена?

Regulatory safety information indicates that Фосфадена is associated with side effects such as dizziness and blurred vision. If patients experience these or other central nervous system effects, they may be cautioned against driving or operating machinery, as these activities require full concentration and coordination.

Storage and Disposal Requirements

Фосфадена tablets (Adenosine Phosphate) must be stored strictly according to official regulatory specifications to maintain product quality.

Storage Conditions

Requirement	Specification
Temperature	Do not store above 25, C (77, F). Do not freeze or refrigerate.
Protection	Store in a dry, dark place and protect from light and moisture.
Packaging	Keep the tablets in their original container until use.
Safety	Keep the medication out of the sight and reach of children.

Disposal of Unused Product

Do not dispose of Фосфадена таблетки via household waste or wastewater. Any unused or expired product must be discarded in accordance with local regulatory requirements for pharmaceutical waste.